Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A phase II study (Immunocabo)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516972-14-00

Enrollment

Registered

2024-10-28

Start date

2020-01-30

Completion date

2025-06-19

Last updated

2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Brief summary

PFS on cabozantinib treatment (considering as PFS events: clinical or radiological progressive disease, per RECIST 1.1, or death).

Detailed description

Objective Response Rate (ORR) as per RECIST 1.1, duration of response, Treatment Time Failure (TTF), Time to Progression (TTP), and Overall Survival (OS)., To evaluate the safety and tolerability, according to NCI-CTCAE v.5

Interventions

DRUGCABOMETYX 60 mg film-coated tablets

DRUGCABOMETYX 20 mg film-coated tablets

DRUGCABOMETYX 40 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS on cabozantinib treatment (considering as PFS events: clinical or radiological progressive disease, per RECIST 1.1, or death).	—

Secondary

Measure	Time frame
Objective Response Rate (ORR) as per RECIST 1.1, duration of response, Treatment Time Failure (TTF), Time to Progression (TTP), and Overall Survival (OS)., To evaluate the safety and tolerability, according to NCI-CTCAE v.5	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026